Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003

Autor: James French, Gilbert C. White, Joan Cox Gill, Felicia Kiplinger, Richard Lipton, James J. Goedert, Melinda E Nolte, Charles Cooper, Brittan Browning, Kathryn Galli, Nigel S. Key, Anastasia Karafoulidou, Craig M. Kessler, Christine Guelcher, Michael W. Fried, Howard A. Britton, Amy D. Shapiro, Catherine S. Manno, Naomi L.C. Luban, Aime L. Grimsley, Cindy A. Leissinger, Johanna McCarthy, John J. Hutter, Alexis A. Thompson, Dorine Belliveau, Michael Lammer, Anne L. Angiolillo, Keith Hoots, Zale P. Bernstein, Willis H. Navarro, Anastasia E. Lee, Jeanne M. Lusher, Ilene Goldberg, Muriel Herr, Linda Percy, Gina Stack, Kevin McRedmond, Kay Miller, Amanda Wade, Christine Pece, Richard S. Lemons, Sandra Hibner, Deborah L Brown, Jodie Nelson, Cecilia V. Schmidt, Charles Sexauer, Anita Smith, Prasad Matthew, Barbara A. Konkle, Kenneth E. Sherman, Sheldon H. Rubin, Hernan Sabio, Vicky Hannemann, M. Ullman, Judy A. Bagato, Donna DiMichele, Jerry S. Powell, Regina Butler, Marilyn J. Manco-Johnson, Patti Noblet, Lori Laudenbach, Kathi Cobb, Madeline Heffner, Arthur R. Thompson, Marcus E. Carr, Ralph A. Gruppo, Sheryl Giambartolomei, Suzi Greer, J. E. Palascak, Donald Lilley, Jaime Siegel, Louis M. Aledort, Michael M. Lederman, Marge Halley, Nirmala Vijayanathan, Linda Belling, Jessie Roth, Steven Klintworth, Shirley Bleak, Diane J. Nugent, Michael D. Tarantino, Jorge DiPaolo, Lawrence Jardine, Rathi V. Iyer, Mary Lou Damiano, Karen Scott, Anne T. Neff, Steven Faust, Susan Gamerman, Hans Joachim Reimers, Eric H. Kraut, Marcia Schwartz, M. Elaine Eyster, Gillian Jenkins, Marianne McDaniel, Leslie Witkoff, James P. Steinberg, Marion Dugdale, Janice S. Withycombe

Publikováno v: Haemophilia. 11:516-528

Before the mid-1980s, haemophilia often was unknowingly treated with contaminated plasma products, resulting in high rates of human immunodeficiency virus (HIV-1), hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. To estimate the impact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d8c4b2f8f2af6fe1653d8d9cdd9225a
https://doi.org/10.1111/j.1365-2516.2005.01138.x

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia

Autor: M L Manco-Johnson, Leonard A. Valentino, Desiree Medeiros, Prasad Mathew, Amy D. Shapiro, Nattee Narkbunnam, J. Michael Soucie, Brenda Riske, Harlan Austin, Gregory Thomas, Ray F. Kilcoyne, Linda J. Jacobson, Genlin Hu, W. Keith Hoots, L. J. Jacobson, Paul E. Monahan, Michael Recht, Sharon Funk, Donna DiMichele, J. David Ingram, Diane J. Nugent, Richard Jude Samulski, Bruce L. Evatt, Thomas C. Abshire, Deborah L Brown, Shirley Bleak, Alan R. Cohen, Aravind Asokan, Alexis A. Thompson, Michele R. Hacker, Marilyn J. Manco-Johnson, Alison Matsunaga, George R. Buchanan, Cindy A. Leissinger, M. J. Manco-Johnson, Chengwen Li, Kevin McRedmond

Publikováno v: Gene therapy. 19(3)

Recombinant adeno-associated virus (rAAV) is a promising gene delivery vector and has recently been used in patients with hemophilia. One limitation of AAV application is that most humans have experienced wild-type AAV serotype 2 exposure, which freq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffe25dafb23d018df26e418031d4f436
https://pubmed.ncbi.nlm.nih.gov/21697954